<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES AND EXCHANGE ACT OF 1934
--------------------------
March 1, 1995
(Date of Report)
------------------
February 23, 1995
------------------
(Date of Earliest Event Reported)
PFIZER INC.
(Exact name of registrant as specified in its Charter)
DELAWARE 1-3619 13-531570
(State or other jurisdiction (Commission (I.R.S.
of incorporation) File Number) Identification No.)
235 EAST 42ND STREET, NEW YORK, NEW YORK 10017
(Address of principal executive offices) (Zip Code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING
AREA CODE (212) 573-2323
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
-2-
ITEM 5. OTHER EVENTS
On February 23, 1995, Pfizer Inc. ("Pfizer") announced that barring unusual
circumstances its Board of Directors would vote on a two-for-one split of
Pfizer common stock on April 27, 1995. The Board intends to act on the
proposal in a session that follows Pfizer's Annual Meeting on April 27, 1995.
At the Annual Meeting, shareholders will vote on a proposal to increase the
authorized shares of Pfizer common stock and to reduce the par value of the
Pfizer common stock.
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PFIZER INC.
(Registrant)
By: /s/Terence J. Gallagher
---------------------------------------
Terence J. Gallagher
Vice President - Corporate Governance
Date: March 1, 1995
